ArticleCureus2025
Approach to Detecting Beneficial and Detrimental Drug-Drug Interactions in Complex Pharmacotherapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The increasing prevalence of polypharmacy has raised concerns about drug-drug interactions (DDIs) and their impact on patient safety. Database-based DDI detection often suffers from insufficient patient background information and missing data, limiting the accuracy and applicability of DDI assessments. A novel model is needed to overcome these limitations and provide a more comprehensive evaluation of DDIs to enhance patient safety in the context of multiple medication use. Objectives This study aims to develop and validate a novel model for evaluating both the beneficial and detrimental effects of DDIs on patient safety. The model is designed to address challenges associated with insufficient patient background information and missing data in database studies while providing a comprehensive assessment of DDIs using statistical inference and hypothesis tests. Methods To address the challenges of insufficient patient background information and missing data often encountered in database studies, the proposed model incorporates an overlap parameter. This parameter represents the degree of commonality in patient profiles susceptible to adverse events from individual drug administrations. The magnitude of DDIs is presented in a 2×2 contingency table constructed by the occurrence or non-occurrence of specific adverse events in observed value and expected value estimated from the model. This tabular format facilitates the assessment of DDIs using statistical inference and hypothesis tests. Results Simulations under various settings confirmed that significance levels for statistical hypothesis tests were strictly observed. Furthermore, applications to real-world databases demonstrated that the proposed model effectively identifies both positive and negative DDIs. Conclusions This research provides healthcare professionals with a robust and practical tool for enhanced DDI detection and management. The presentation of findings in a familiar 2×2 contingency table format improves the accessibility of our results, facilitating straightforward interpretation. The proposed model has the potential to promote a safer healthcare environment for patients on multiple medications, ultimately enhancing patient safety and treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.